New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 5, 2012
08:31 EDTRGRXRegeneRx receives notice of allownace from U.S. Patent Office for new indication
RegeneRx Biopharmaceuticals has received a Notice of Allowance of a U.S. patent for the use of Thymosin beta 4, certain fragments, isoforms, derivatives and analogues to treat patients with glaucoma and elevated intraocular pressure. Glaucoma refers to a group of eye conditions that lead to damage to the optic nerve. This nerve carries visual information from the eye to the brain. In most cases, damage to the optic nerve is due to increased pressure in the eye, known as intraocular pressure. Glaucoma is the second most common cause of blindness in the United States. The patent will expire in 2026.
News For RGRX From The Last 14 Days
Check below for free stories on RGRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2014
12:39 EDTRGRXRegeneRx receives notice of allowance for U.S. patent for treatment of stroke
RegeneRx Biopharmaceuticals announced that it has received a Notice of Allowance for a second U.S. patent for treating central nervous system injuries and disorders using Thymosin beta 4 to regenerate damaged tissue. In this case, the patent will be for the treatment of patients suffering a stroke. Researchers at the Henry Ford Hospital in Detroit, Michigan, discovered Tβ4ís effects in animal studies performed under a Material Transfer Agreement between the Institution and RegeneRx. RegeneRx has received a license to the intellectual property. The patent will expire in 2026.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use